JP2020200332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020200332A5 JP2020200332A5 JP2020140379A JP2020140379A JP2020200332A5 JP 2020200332 A5 JP2020200332 A5 JP 2020200332A5 JP 2020140379 A JP2020140379 A JP 2020140379A JP 2020140379 A JP2020140379 A JP 2020140379A JP 2020200332 A5 JP2020200332 A5 JP 2020200332A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- group
- binding fragment
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 26
- 102000036639 antigens Human genes 0.000 claims 26
- 108091007433 antigens Proteins 0.000 claims 26
- 239000012634 fragment Substances 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 21
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 10
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 10
- 102000013814 Wnt Human genes 0.000 claims 9
- 230000011664 signaling Effects 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 claims 3
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 claims 3
- 101000802406 Homo sapiens E3 ubiquitin-protein ligase ZNRF3 Proteins 0.000 claims 3
- 102000006083 ZNRF3 Human genes 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 230000017423 tissue regeneration Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 229960001254 vildagliptin Drugs 0.000 claims 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 2
- 208000004300 Atrophic Gastritis Diseases 0.000 claims 1
- 206010012742 Diarrhoea infectious Diseases 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000036495 Gastritis atrophic Diseases 0.000 claims 1
- 101001063463 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 4 Proteins 0.000 claims 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 1
- 101000981765 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 6 Proteins 0.000 claims 1
- 201000010538 Lactose Intolerance Diseases 0.000 claims 1
- 102100031035 Leucine-rich repeat-containing G-protein coupled receptor 4 Human genes 0.000 claims 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims 1
- 102100024140 Leucine-rich repeat-containing G-protein coupled receptor 6 Human genes 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010049416 Short-bowel syndrome Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000020788 dietary exposure Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161547209P | 2011-10-14 | 2011-10-14 | |
| US61/547,209 | 2011-10-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017192565A Division JP2018016634A (ja) | 2011-10-14 | 2017-10-02 | Ｗｎｔ経路関連疾患のための抗体および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020200332A JP2020200332A (ja) | 2020-12-17 |
| JP2020200332A5 true JP2020200332A5 (enExample) | 2021-02-04 |
| JP7079298B2 JP7079298B2 (ja) | 2022-06-01 |
Family
ID=47278355
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535221A Withdrawn JP2014530816A (ja) | 2011-10-14 | 2012-10-12 | Ｗｎｔ経路関連疾患のための抗体および方法 |
| JP2017192565A Withdrawn JP2018016634A (ja) | 2011-10-14 | 2017-10-02 | Ｗｎｔ経路関連疾患のための抗体および方法 |
| JP2020140379A Active JP7079298B2 (ja) | 2011-10-14 | 2020-08-21 | Ｗｎｔ経路関連疾患のための抗体および方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014535221A Withdrawn JP2014530816A (ja) | 2011-10-14 | 2012-10-12 | Ｗｎｔ経路関連疾患のための抗体および方法 |
| JP2017192565A Withdrawn JP2018016634A (ja) | 2011-10-14 | 2017-10-02 | Ｗｎｔ経路関連疾患のための抗体および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9296826B2 (enExample) |
| EP (2) | EP3653222A1 (enExample) |
| JP (3) | JP2014530816A (enExample) |
| CN (2) | CN104080471B (enExample) |
| ES (1) | ES2769786T3 (enExample) |
| WO (1) | WO2013054307A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| CN106167526A (zh) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| RU2017120287A (ru) | 2012-02-28 | 2018-11-15 | АйАрЭм ЭлЭлСи | ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| CA2878868A1 (en) | 2012-07-13 | 2014-01-16 | Austin L. Gurney | Rspo3 binding agents and uses thereof |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| BR112016008477A2 (pt) | 2013-10-18 | 2017-10-03 | Genentech Inc | Corpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo |
| JP2017518040A (ja) * | 2014-04-21 | 2017-07-06 | アッヴィ・ステムセントルクス・エル・エル・シー | 新規の抗ｒｎｆ４３抗体および使用方法 |
| NZ728488A (en) * | 2014-07-29 | 2023-03-31 | Shenzhen Hightide Biopharmaceutical Ltd | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| WO2017020974A1 (en) * | 2015-08-03 | 2017-02-09 | Institut Pasteur | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy |
| EP4169942A1 (en) | 2016-03-11 | 2023-04-26 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
| EP3865511A1 (en) | 2016-04-14 | 2021-08-18 | F. Hoffmann-La Roche AG | Anti-rspo3 antibodies and methods of use |
| US11993645B2 (en) * | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
| WO2018140821A1 (en) * | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
| US11746150B2 (en) | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| CA3085596A1 (en) | 2017-12-19 | 2019-06-27 | Surrozen, Inc. | Anti-frizzled antibodies and methods of use |
| AU2019301633A1 (en) * | 2018-07-09 | 2021-01-28 | Surrozen Operating, Inc. | Tissue-specific Wnt signal enhancing molecules and uses |
| US20220064337A1 (en) * | 2018-12-19 | 2022-03-03 | Surrozen, Inc. | Antigen binding formats for receptor complexes |
| US20220041753A1 (en) * | 2018-12-27 | 2022-02-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bispecific antibody for membrane clearance of target receptors |
| EP3986912A1 (en) | 2019-06-21 | 2022-04-27 | Regeneron Pharmaceuticals, Inc. | Treatment of decreased bone mineral density with zinc and ring finger 3 (znrf3) inhibitors |
| AU2020376928A1 (en) * | 2019-11-01 | 2022-05-19 | The Regents Of The University Of California | Degradation of surface proteins using bispecific binding agent |
| US12441984B2 (en) | 2019-11-08 | 2025-10-14 | Kansas State University Research Foundation | Isolation, preservation, and expansion of canine umbilical cord mesenchymal stromal cells |
| WO2021140209A1 (en) * | 2020-01-10 | 2021-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Rspo1 proteins and their use |
| CA3169792A1 (en) * | 2020-03-05 | 2021-09-10 | Umc Utrecht Holding B.V. | Membrane ubiquitin ligases to target protein degradation |
| CN111920951B (zh) * | 2020-07-17 | 2022-12-06 | 上海交通大学医学院附属瑞金医院 | Znrf3/rnf43在制备调节能量代谢药物中的应用 |
| JP2023549854A (ja) | 2020-11-16 | 2023-11-29 | スロゼン オペレーティング， インコーポレイテッド | 肝臓特異的Ｗｎｔシグナル増強分子およびその使用 |
| WO2022169872A1 (en) * | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| DE3853515T3 (de) | 1987-05-21 | 2005-08-25 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| KR101008758B1 (ko) | 2001-09-18 | 2011-01-14 | 제넨테크, 인크. | 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물 |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| EP2233572A3 (en) | 2002-06-06 | 2011-01-12 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human colon cancers |
| CA2501235A1 (en) | 2002-10-04 | 2004-04-22 | The Regents Of The University Of California | Methods for treating cancer by inhibiting wnt signaling |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| EP1771207A4 (en) | 2004-07-09 | 2009-05-27 | Univ California | METHOD FOR THE PREVENTION OF CANCER USING AGENTS THAT RESIST WNT16 SIGNALING |
| WO2007027509A2 (en) | 2005-08-31 | 2007-03-08 | Biogen Idec Ma Inc. | Evaluating and treating scleroderma |
| US20090047276A1 (en) * | 2007-05-15 | 2009-02-19 | University Of Washington | Methods for increasing cell or tissue regeneration in a vertebrate subject |
| JP5931336B2 (ja) | 2007-07-02 | 2016-06-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | がんを処置および診断するための組成物および方法 |
| ES2560532T3 (es) * | 2007-11-02 | 2016-02-19 | Novartis Ag | Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6) |
| WO2010016766A2 (en) * | 2008-08-08 | 2010-02-11 | Koninklijke Nederlandse Akademie Van Wetenschappen | Antibodies recognizing endogenous human lgr5 and/or lgr6 |
| GB201111244D0 (en) * | 2011-06-30 | 2011-08-17 | Konink Nl Akademie Van Wetenschappen Knaw | Culture media for stem cells |
| WO2011004379A1 (en) | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
| GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
| RU2017120287A (ru) | 2012-02-28 | 2018-11-15 | АйАрЭм ЭлЭлСи | ОТБОР БОЛЬНЫХ РАКОМ ДЛЯ ВВЕДЕНИЯ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ Wnt НА ОСНОВАНИИ СТАТУСА МУТАЦИИ RNF43 |
-
2012
- 2012-10-12 JP JP2014535221A patent/JP2014530816A/ja not_active Withdrawn
- 2012-10-12 CN CN201280060847.8A patent/CN104080471B/zh active Active
- 2012-10-12 EP EP19209759.0A patent/EP3653222A1/en not_active Withdrawn
- 2012-10-12 ES ES12794776T patent/ES2769786T3/es active Active
- 2012-10-12 CN CN201810805989.1A patent/CN109111523B/zh active Active
- 2012-10-12 EP EP12794776.0A patent/EP2766033B1/en active Active
- 2012-10-12 US US14/351,410 patent/US9296826B2/en active Active
- 2012-10-12 WO PCT/IB2012/055560 patent/WO2013054307A2/en not_active Ceased
-
2016
- 2016-03-17 US US15/073,156 patent/US20180066067A1/en not_active Abandoned
-
2017
- 2017-10-02 JP JP2017192565A patent/JP2018016634A/ja not_active Withdrawn
-
2020
- 2020-08-21 JP JP2020140379A patent/JP7079298B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020200332A5 (enExample) | ||
| JP6206972B2 (ja) | グルカゴン様ペプチド−２組成物およびその作製法および使用法 | |
| CN101541957B (zh) | 利尿钠多肽 | |
| KR101200227B1 (ko) | 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체 | |
| JP2019510739A5 (enExample) | ||
| JP2013517783A5 (enExample) | ||
| JP2008536483A5 (enExample) | ||
| Gulati et al. | A Novel Neuroregenerative Approach Using ET B Receptor Agonist, IRL-1620, to Treat CNS Disorders. | |
| US20240239856A1 (en) | Compositions, formulations and interleukin production and purification | |
| JP2004504032A5 (enExample) | ||
| JP2009213477A5 (enExample) | ||
| JP2015525768A (ja) | 抗炎症活性を有するペプチド、及びそれを含む組成物 | |
| WO2005025616A1 (ja) | 抗体の用途 | |
| JP2012500001A5 (enExample) | ||
| JP2017531613A5 (enExample) | ||
| JP2015527357A (ja) | 単一可変ドメインとカモスタットメシル酸塩（ｃｍ）とを含んでなる組成物 | |
| JP2006506942A5 (enExample) | ||
| JP2017221201A5 (enExample) | ||
| JPH03501968A (ja) | オリゴペプチド、及びａｉｄｓまたはａｒｃの診断及びワクチン接種を目的としたそれらの用途 | |
| Al Musaimi | FDA's stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond | |
| US20190142913A1 (en) | Grp78 antagonist that block binding of receptor tyrosine kinase orphan receptors as immunotherapy anticancer agents | |
| JPWO2021229076A5 (enExample) | ||
| JP2022049715A (ja) | インスリン分泌促進ペプチド | |
| US20250326795A1 (en) | Use of d-enantiomeric peptide ligands of monomeric tau for the therapy of various tauopathies | |
| JP2005538041A5 (enExample) |